نتایج جستجو برای: teriparatide
تعداد نتایج: 877 فیلتر نتایج به سال:
A breakthrough in understanding of mechanisms of bone structure regulation has brought about the introduction of the new synthetic recombinant human parathyroid hormone 1-34 (PTH1-34; Teriparatide) in the treatment of osteoporosis. These mechanisms, involving the RANKL, RANK, and osteoprotegerin system, are also known to be involved in malignant myeloma (MM) and tumor and bone metastasis develo...
Background and purpose: Osteoporosis is the most common metabolic bone disease. The aim of this study was to evaluate the effects of teriparatide on the incidence of fractures and bone density in postmenopausal women with osteoporosis. Materials and methods: A clinical trial was performed in all postmenopausal women aged 45-75 years old with osteoporosis attending a teaching hospital affiliate...
To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture...
Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis in Iran
Background: Teriparatide is a new agent serves as a treatment of choice for severe post-menopausal osteoporotic patients who are at a high risk of fracture or have failed or been intolerant of previous osteoporosis therapy. The objective of this study is estimating the cost-utility of Teriparatide compared with no treatment from health system perspective in Iran. Method: A microsimulation...
Background: Hip, vertebral and wrist fractures are the most common consequences of osteoporosis. This study aimed at analyzing the cost-effectiveness of teriparatide (CinnoPar®), compared with alendronate and risedronate, in the treatment of women aged 60 and over with postmenopausal osteoporosis in Iran. Methods: A decision tree model with a 2-year time hor...
Bone material properties and response to teriparatide in osteoporosis due to WNT1 and PLS3 mutations
Patients with osteoporosis-associated WNT1 or PLS3 mutations have unique bone histomorphometric features and osteocyte-specific hormone expression patterns. To investigate the effects of on material properties. Transiliac biopsies were evaluated by quantitative backscattered electron imaging, immunohistochemistry, histomorphometry. Ambulatory patients. Three pediatric eight adult patients mutat...
Teriparatide administered by daily subcutaneous injection, was approved in the United States in 2002, and has been the only anabolic medication available in the United States for almost 13 years. Outside the US, teriparatide is joined only by intact PTH (1–84) as anabolic therapy for osteoporosis treatment. Although both anabolic and antiresorptive medications improve bone density and strength,...
To the Editor: We read with great interest the case reported by Lee et al in the Early View section of the journal, presenting a case of aledronate-induced osteonecrosis of the jaws (ONJ), which healed following teriparatide administration. The authors conclude that teriparatide can be an important adjuvant to other measures in the management of ONJ that should be considered prior to major rese...
Teriparatide (recombinant human 1-34 parathyroid hormone) has been registered for the treatment of postmenopausal osteoporosis and osteoporosis in men for more than 5 years, whereas 1-84 parathyroid hormone has just recently been registered in Europe for osteoporosis management. Therefore, more data are available regarding the long-term safety of teriparatide. The issues to be considered are th...
STUDY DESIGN Retrospective case series. PURPOSE To examine the most effective duration of teriparatide use for spinal fusion in women with postmenopausal osteoporosis. OVERVIEW OF LITERATURE We reported that daily subcutaneous injection of teriparatide (parathyroid hormone) significantly improved bone union after instrumented lumbar posterolateral fusion (PLF) in women with postmenopausal o...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید